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Abstract
Background:  Antisense oligonucleotides against hTR (As-ODN-hTR) have shown promising
results as treatment strategies for various human malignancies. All-trans retinoic acid (ATRA) is a
signalling molecule with important roles in differentiation and apoptosis. Biological responses to
ATRA are currently used therapeutically in various human cancers. The aim of this study was to
evaluate the anti-tumor effects of As-ODN-hTR combined with ATRA in vivo.
Methods: In situ human oral squamous cell carcinoma (OSCC) models were established by
subcutaneous injection of Tca8113 cells. Mice were treated with sense oligonucleotides against
hTR(S-ODN-hTR) alone, As-ODN-hTR alone, ATRA alone, As-ODN-hTR plus ATRA, or S-
ODN-hTR plus ATRA. Tumor size and weight were assessed in the mice. Telomerase activity was
detected by a TRAP assay, apoptotic cells were evaluated with a Tunel assay, the expression of
apoptosis-related proteins (Bcl-2 and Bax) was evaluated by immunohistochemistry and
ultrastructural morphological changes in the tumor specimen were examined.
Results: Both As-ODN-hTR and ATRA can significantly inhibit tumor growth in this OSCC
xenograft solid-tumor model, and the combination of the two agents had a synergistic anti-
tumorogenic effect. We also demonstrated that this anti-tumor effect correlated with inhibition of
telomerase activity. Furthermore, significant increases in the number of apoptotic cells, typical
apoptotic morphology and a downregulation of the anti-apoptotic protein, bcl-2 were observed in
the treated tissues.
Conclusion: The combination of As-ODN-hTR and ATRA has a synergistic anti-tumor effect. This
anti-tumor effect can be mainly attributed to apoptosis induced by a decrease in telomerase
activity. Bcl-2 plays an important role in this process. Therefore, combining As-ODN-hTR and
ATRA may be an approach for the treatment of human oral squamous cell carcinoma.
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Background
Head and neck cancer affects more than half a million
patients worldwide each year. Despite improvements in
surgery, chemotherapy, and radiation therapy, overall sur-
vival has not improved over the past 30 years. Therefore,
the development of more effective therapeutic tools and
strategies is urgently required.
Telomerase is a ribonucleoprotein that adds telomeric
repeats (TTAGGG)n to the ends of chromosomes. Telom-
erase expression is now believed to be an important step
in the development of cellular immortality and oncogen-
esis. Recently, it has been shown that approximately 90%
of malignant tumors of various origins express telomer-
ase, whereas most normal tissues do not [1]. The human
telomerase holoenzyme consists of the human telomerase
RNA template subunit (hTR), the human telomerase
reverse transcriptase (hTERT) and a number of associated
proteins. Both the telomerase RNA component hTR and
hTERT are essential for telomerase function, therefore
these components may be good candidates for targeted
therapy of malignant tumors [2]. Strategies using anti-
sense oligonucleotides (As-ODN) against hTR (As-ODN-
hTR) have shown promising results as treatment strategies
for various human malignancies [3,4]. However, since
antisense therapy was unable to completely inhibit telom-
erase activity and directly kill tumor cells in vivo, it was
suggested that this strategy would have to be combined
with another approach in order to provide an adequate
level of therapy.
All-trans retinoic acid (ATRA), a vitamin A derivative, is a
signalling molecule with important roles in growth, dif-
ferentiation, and apoptosis in a variety of normal adult
and embryonic tissues. These functions of ATRA are partly
mediated by mechanisms that inhibit telomerase activity
[5]. Biological responses to ATRA are currently used ther-
apeutically in various human cancers including leukemia,
skin cancer, cervical cancer and neuroblastoma [6-8]. The
ability of ATRA to modulate differentiation, apoptosis,
and proliferation of tumor cells through inhibition of tel-
omerase has been suggested to explain its efficacy against
tumors [9,10]. Based on this hypothesis, we postulated
that the combination of As-ODN-hTR and ATRA therapy
might have synergistic anti-tumor effects.
We have previously reported that the combination of oli-
gonucleotide (a synthesized 19-mer) As-ODN-hTR treat-
ment with ATRA had a cytotoxic effect on oral squamous
cell carcinoma (Tca8113) in vitro, in a synergistic manner
[11]. The aim of this study was to evaluate the in vivo anti-
tumor effects of As-ODN-hTR combined with ATRA in an
in situ human oral squamous cell carcinoma (OSCC)
model in mice.
Methods
Antisense oligodeoxynucleotides and drugs
The antisense phosphorothioate oligonucleotide (As-
ODN-hTR) targeting bases 65 to 46 of hTR mRNA (5'-ccct-
tctcagttagggttag-3') and the hTR-Sense phosphorothioate
oligonucleotide (S-ODN-hTR) (5'-ctaaccctaactgagaaggg-
3') were synthesized with partial thio-modifications by
Shanghai ShenBioColor Company. The sense sequence
was used as a control. ATRA (Sigma, U.S.A.) was dissolved
in seed oil at concentration of 3 mg/ml and shielded from
the light with aluminium foil until used.
Cell culture and experimental animals
Tca8113, a cell line derived from a human primary oral
squamous cell carcinoma, was maintained in RPMI-1640
with 10% fetal bovine serum (FBS) at 37°C in an atmos-
phere with 5% CO2.
The virgin female nu/nu BALB/c mice (4 weeks old; 19 ±
2 g) used in these experiments were obtained from the
Shanghai Laboratory Animal Center of China Academy of
Sciences. All animal experiments were carried out accord-
ing to the standards of animal care as outlined in the
Guide for the Care and Use of Experimental Animals of
Medical College of Shanghai Jiaotong University. The
human OSCC tumor model has been previously
described [12]. Briefly, the Tca8113 cells were harvested
by trypsinization and resuspended at a concentration of 1
× 107  cells/ml. The mice were then subcutaneously
implanted with 1 × 106 cells into both the right and left
hind limbs using a 27 gauge needle/0.5 ml tuberculin
syringe. Seven days later, when tumor nodules were pal-
pable, mice were randomly assigned to one of six groups:
S-ODN-hTR alone (S group); As-ODN-hTR alone (As
group); ATRA alone (ATRA group); S-ODN-hTR plus
ATRA (S/ATRA group); As-ODN-hTR plus ATRA (As/ATRA
group) and no treatment (control group). There were five
mice in each group.
Treatment in Nude Mice
Fourteen days after tumor inoculation, when the subcuta-
neous tumor had grown to a visible size, the different
treatments were administered to the established tumor.
The As group received an intra-tumoral injection of As-
ODN-hTR DNA (1 mg/kg in a volume of 50 μl) three
times a week for four weeks. The S group received an intra-
tumoral injection of S-ODN-hTR DNA (1 mg/kg in a vol-
ume of 50 μl) three times a week for four weeks. Mice of
ATRA group were gavaged ATRA daily at a dose of 15 mg/
kg/d for four weeks. The As/ATRA group received both an
intra-tumoral injection of As-ODN-hTR DNA and ATRA
administration. The S/ATRA group received both intra-
tumoral injection of S-ODN-hTR DNA and ATRA admin-
istration. The control group received intra-tumoral injec-
tion of the same volume of phosphate buffered saline. AtBMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
Page 3 of 9
(page number not for citation purposes)
the study endpoint, mice were sacrificed by cervical dislo-
cation and the tumors were removed and weighed. Tumor
sizes were monitored with calipers twice a week, and the
tumor volume (V, mm3) was calculated as (L × W2)/2,
where L = length (mm) and W = width (mm). The per-
centage of tumor growth inhibition was calculated as:
Inhibitory rate (%) = (Weightcontrol-Weighttreat)/Weightcon-
trol × 100.
Tissue specimens
A total of 60 tissue specimens were obtained after sacrific-
ing the animals. The samples were immediately cut into
three parts. One part was frozen in liquid nitrogen, and
stored at -80°C until examined. The second part was fixed
in 10% buffered formalin, and fragments were embedded
in paraffin before sections (4 μm) were cut. The third part
was fixed with 4% glutaraldehyde in phosphate buffer for
further transmission electronic microscopy analysis. Care
was taken to use separate instruments to harvest each
specimen in order to avoid cross contamination.
Terminal deoxynucleotidyl transferase (TDT) dUTP nick 
end labelling (TUNEL)
Evaluation of apoptotic cells was performed using a Tunel
assay, using an in situ Cell Death Detection kit (Oncor,
U.S.A.). Briefly, the paraffin sections were treated with 20
μg/ml proteinase K for 15 min and blocked with 3%
hydrogen peroxide in methyl alcohol for 10 min. After
washing in PBS, sections were incubated with equilibra-
tion buffer, followed by TDT enzyme in a humidified
chamber at 37°C for 1 hr, and then a stop/wash buffer
was applied for 30 min at 37°C. Finally, the sections were
incubated with peroxidase labelled anti-digoxigenin anti-
body for 30 min at room temperature. Positive cells were
visualized using a diaminobenzidine substrate and coun-
terstained with hematoxylin. TUNEL positive cells
showed brown staining of the nucleus suggestive of inter-
nucleosomal DNA cleavage.
Immunohistochemistry (IHC)
IHC for Bcl-2 and Bax was performed using standard
methods [13]. Endogenous peroxidase activity was
blocked by treatment with 3% hydrogen peroxide in PBS
for 30 min. The specimens were rinsed in PBS. The tissue
sections were stained with a mouse monoclonal anti-Bcl-
2 antibody (DAKO, Denmark) and a rabbit polyclonal
anti-Bax antibody (Santa Cruz, U.S.A.). The sections were
incubated overnight at 4°C (dilution of primary antibod-
ies 1:50). The bound antibody was detected with a sec-
ondary biotinylated antibody for 30 min at room
temperature (1:200 dilution) and visualized using diami-
nobenzidine as a chromogenic substrate. The sections
were then counterstained with hematoxylin.
Transmission electron microscopy (TEM)
For ultrastructural examination, ultra-thin sections were
cut on a Reichert Ultracut ultramicrotome (Mager Scien-
tific Inc., U.S.A.), mounted on 150-mesh copper grids,
and post-stained in uranyl acetate and Reynold's lead cit-
rate. Sections were photographed using a transmission
electronic microscope (PHILIP CM-120).
Evaluation of TUNEL and IHC Staining results
The levels of TUNEL and IHC staining were quantified
using a semi-automated computerized image analysis sys-
tem. The image analysis software program used was Image
Pro Plus 6.0, which has previously been successfully
applied to analyze histological sections [14,15]. The Inte-
grated Optical Density (IOD, equal to Area × Average
Optical Density) of positive staining was calculated for
each tissue section. The average IOD scores were calcu-
lated from triplicate values from each section. The image
analysis was performed by three pathologists blinded to
the treatment group.
Measurement of telomerase activity by TRAP assay
Batches of frozen biopsies were thawed on ice and
homogenized in telomerase assay buffer. The protein con-
centration of the supernatant was determined using a Pro-
tein Assay Kit (Pierce Biotechnology, U.S.A.). 1 μg of
protein was then analyzed using a TRAP (Telomeric
Repeat Amplification Protocol) assay (Roche, Germany)
to quantify telomerase activity. Briefly, this protocol con-
sisted of incubating the protein lysate with an artificial tel-
omerase template, allowing the telomerase to extend the
template. The elongated products were then amplified by
PCR using biotin-labelled telomere-specific primers. Aliq-
uots of the PCR products were denatured, hybridized to
DIG-labelled sequence-specific probes and bound to
streptavidin-coated microtiter plates. The products were
detected with peroxidase conjugated anti-DIG antibodies
and TMB as a substrate. The optical density (OD) was read
at 450 nm against a blank (reference wavelength 620 nm).
Each sample was measured twice.
Statistical analysis
Results were expressed as mean ± standard error (SE). Sta-
tistical differences between groups were evaluated by one-
way analysis of variance (ANOVA), and two-way ANOVA
was used to determine interactions between As-ODN-hTR
and ATRA. All data were analyzed with SPSS 10.0 soft-
ware. P < 0.05 was considered statistically significant. The
combined anti-tumor effect of As-ODN-hTR and ATRA
was evaluated using the fractional product method. Frac-
tional tumor volume (FTV) relative to controls was calcu-
lated as the ratio between the mean tumor volume of the
experimental groups and the mean tumor volume of the
control group. The expected FTV of the combination is the
product of the mean FTV of the two treatments. The ratioBMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
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was obtained by dividing the expected FTV by the
observed FTV of the combination. An FTV ratio of >1 indi-
cates a synergistic effect, and a ratio of <1 indicates a less
than additive effect.
Results
Effects of different antisense ODNs on tumor growth
In the current study, we tested the influence of S-ODN, As-
ODN, ATRA, As-ODN plus ATRA, or S-ODN plus ATRA
on the growth rate of Tca8113 tumors in vivo. As shown in
Figure 1, at the end of treatment the mean tumor size and
tumor weight were 740.8 ± 147.4 mm3 and 0.504 ± 0.101
g in the S group, 422.7 ± 77.8 mm3 and 0.26 ± 0.043 g in
the As group, 544.7 ± 93.3 mm3 and 0.294 ± 0.054 g in the
ATRA group, 564.9 ± 107.8 mm3 and 0.319 ± 0.054 g in
the S/ATRA group and 240.4 ± 40.9 mm3 and 0.123 ±
0.031 g in the As/ATRA group, respectively. In contrast,
tumor volume and tumor weight in the control group
were 796.2 ± 133.7 mm3 and 0.522 ± 0.109 g, respec-
tively. Both As-ODN and ATRA treatment resulted in a
reduction in tumor volume and tumor weight when com-
pared to the control group (P < 0.01, one-way ANOVA).
However, no tumor inhibition was observed in the S-
ODN treated group.
Treatment of mice with a combination of As-ODN and
ATRA resulted in a significant enhancement of the reduc-
tion in tumor growth when compared with therapy with
either As-ODN (P < 0.01) or ATRA alone (P < 0.01). Sta-
tistical analysis indicated that a highly significant interac-
tion exists between As-ODN-hTR and ATRA (F = 10.743,
P= 0.002, two-way ANOVA). The anti-tumor efficacy of
As-ODN in combination with ATRA was assessed by a
fractional product method. From day 10 to day 28 after
treatment, the ratio between the expected FTV and the
observed FTV of the combination ranged from 1.05 to
1.27 (Table 1), clearly indicating synergy between As-
ODN-hTR and ATRA treatment.
The effect of the treatment with antisense oligonucleotide against hTR(As-ODN-hTR), all-trans retinoic acid (ATRA) on the  growth of OSCC tumor xenografts in nude mice Figure 1
The effect of the treatment with antisense oligonucleotide against hTR(As-ODN-hTR), all-trans retinoic acid 
(ATRA) on the growth of OSCC tumor xenografts in nude mice. A, tumor growth curve is showed. B, tumor weight 
is given as the mean ± SE (bars) (n = 10). C, representative mice and tumors in each experimental group is shown at the end of 
treatment (L = left side, R = right side). Both As-ODN and ATRA treatment resulted in an inhibition of tumor volume and 
tumor weight as compared to control group. * P < 0.01, one-way ANOVA. In addition, highly significant interactions exist 
between hTR As-ODN and ATRA. * * F = 10.743, P = 0.002, two-way ANOVA. The combination of As-ODN and ATRA 
resulted in a significant enhancement of the reduction in tumor growth when compared with monotherapy of As-ODN or 
ATRA alone (P < 0.01).BMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
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When compared with the control group, the inhibition on
the rate of tumor growth was 50.2%, 43.7%, 38.9%, and
76.4% in the As group, ATRA group, S/ATRA group, and
As/ATRA group, respectively. The greatest growth inhibi-
tion occurred in the combination treated group.
Apoptosis detection
Cell apoptosis was detected by TUNEL staining and
ultrastructural morphological changes were examined by
transmission electron microscopy (TEM). Assessment of
cell death by TUNEL histochemistry revealed a dramatic
increase in TUNEL-positive cells in the As-ODN and ATRA
treated groups, and this increase was extremely high in the
As/ATRA combination group compared to the S and con-
trol groups. (Fig. 2A–F). The average Integrated Optical
Density (IOD) of each group in the TUNEL test was
obtained by a computer-assisted quantification method.
The average IODs in the As-ODN and ATRA treated
groups were significantly increased compared to the S
group and control group (P < 0.01, one-way ANOVA). A
significant interaction was observed between the As-ODN
and ATRA treatments (F = 45.918, P  < 0.01, two-way
ANOVA) (Fig. 2G). From the results of transmission elec-
tron micrography, features associated with the typical
morphology of apoptotic squamous carcinoma cells, such
as nuclear condensation and fragmentation were
observed in cells from the As-ODN and ATRA treated
groups (Fig. 2H).
Semi-quantification of Telomerase Activity
Using a TRAP assay, we found that telomerase activity was
significantly higher in the S group and control group com-
pared to the other treatment groups (P < 0.01, one-way
ANOVA). A significant interaction was observed between
As-ODN-hTR and ATRA treatment (F = 4.507, P = 0.041,
two-way ANOVA). (Fig. 3).
Expression of Bcl-2 and Bax
Both Bcl-2 and Bax specific immunostaining were
restricted to the cytoplasm. Bcl-2 immunostaining was
predominantly found in the S group and the control
group (Fig. 4A–B). However, the expression of Bcl-2 in the
As-ODN and ATRA treated groups was very low, and was
extremely low in the As/ATRA combination group (Fig.
4C–F), The average IODs in the As-ODN and ATRA
treated groups were significantly decreased compared to
the S group and control group (P  < 0.01, one-way
ANOVA).(Fig. 4H). A significant interaction was observed
between As-ODN-hTR and ATRA treatment (F = 35. 836,
P < 0.01, two-way ANOVA). However, the expression of
Bax was similar in all experimental groups (Fig. 4G).
Discussion
It has been hypothesized that in the combination of As-
ODN-hTR and ATRA may have an additive anti-tumor
effect. However, previous reports that may relate to this
hypothesis are very limited. In our previous study, we
reported that the combination of As-ODN-hTR and ATRA
could synergistically inhibit telomerase activity in OSCC
(Tca8113) and induce cell growth arrest [11]. The purpose
of this study was to examine the combined anti-tumor
effects of As-ODN-hTR and ATRA treatment in vivo.
In this study, the effects of As-ODN-hTR and ATRA on the
growth of human OSCC xenografts were evaluated. It was
demonstrated that both As-ODN-hTR and ATRA have
anti-carcinogenic effects in our tumor model. However,
controlled S-ODN-hTR treatment had no effect on tumor
growth, indicating that the observed inhibitory effect was
Table 1: Effect of combined treatment of As-ODN-hTR and ATRA on the growth of tumors.
FTV relative to untreated controlsa
Combination treatment
Treated Dayb As-ODN-hTR ATRA Expectedc Observed Ratio of expected FTV/observed FTVd
3 0.972 0.894 0.869 0.945 0.92
7 0.848 0.883 0.749 0.841 0.891
10 0.957 0.922 0.882 0.794 1.111
14 0.99 0.9 0.89 0.844 1.055
17 0.892 0.877 0.782 0.681 1.149
21 0.753 0.879 0.662 0.531 1.246
24 0.618 0.783 0.484 0.379 1.277
28 0.53 0.684 0.363 0.302 1.202
a FTV, fractional tumor volume, calculated as mean tumor volume experimental/mean tumor volume control.
bDay after tumors treated with agents.
cMean FTV of As-ODN-hTR X mean FTV of ATRA.
dObtained by dividing the expected FTV by the observed FTV. A ratio of >1 indicates a synergistic effect, and a ratio of <1 indicates a less than 
additive effect.BMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
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sequence specific. Moreover, a critical observation was
that there was a clear synergistic anti-tumor efficacy of
combination treatment with As-ODN-hTR and ATRA,
compared with monotherapy. This marked interaction
effect resulted in the highest rate of inhibition of tumor
growth in all experimental groups, strongly supporting
our hypothesis that these two agents have a synergistic
anti-tumor effect, which is consistent with our previous
findings in vitro [11].
In an effort to determine the mechanism behind this syn-
ergistic anti-tumor efficacy, the telomerase activity and
levels of cellular apoptosis in each group was investigated.
Cell apoptosis in treatment groups and control group Figure 2
Cell apoptosis in treatment groups and control group. (A-F) Apoptotic cells were revealed by TUNEL-histochemistry 
assay. Representative microphotographs of Tunel staining of (A) control group, (B) S group, (C) As group, (D) ATRA group, 
(E)S/ATRA group and (F) As/ATRA group. Arrows indicate positive cells. Scale bar = 50 μm. The average Integrated Optical 
Density (IOD) of each group was performed by a computer-assisted quantitation. (G) IOD data is shown as the mean ± SE (n 
= 10). The average IODs in As-ODN and ATRA treated groups were significantly increased as compared to S-ODN group and 
control group. * P < 0.01, one-way ANOVA. Significant interaction was observed between As-ODN and ATRA treatment. * * 
F = 45.918, P < 0.01, two-way ANOVA. (H) Electron microscopy showed typical feature of apoptotic cell in As-ODN and 
ATRA treatment groups. Whereas, no ultrastructural changes were observed in S-ODN group and control group (data not 
shown).BMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
Page 7 of 9
(page number not for citation purposes)
Telomerase activity was investigated using a TRAP assay.
The telomerase activity was decreased in the As-ODN-hTR
and ATRA treatment groups compared to the S and con-
trol groups. Although a potential limitation of oligonucle-
otide monotherapy is bioavailability to tumor tissues
[16], our results demonstrated that intra-tumoral injec-
tion of As-ODN-hTR thrice a week, combined with daily
ATRA treatment could decrease telomerase levels by up to
76.4% compared with control tumors. The combination
of As-ODN-hTR and ATRA had a greater effect on telom-
erase activity inhibition than either of the agents used
alone. This result is consistent with the observations of
tumor growth inhibition. The correlation between telom-
erase activity and tumor inhibition suggests that the abil-
ity of As-ODN-hTR and ATRA to inhibit tumor growth is
due to their suppression of telomerase activity. Many
studies have suggested that the hTERT gene may be the
primary target of ATRA regulation of cellular differentia-
tion [9,10]. The As-ODN-hTR used in the present study
was designed against the hTR component of telomerase.
Therefore, the synergistic telomerase suppression effect
observed after combination treatment may be due to the
fact that the two agents simultaneously act against these
two major telomerase components. Further studies are
required to determine the mechanism by which As-ODN-
hTR and ATRA operate synergistically. Moreover, telomer-
ase inhibitors dependent on mechanisms of telomere
attrition would need to be continuously administered on
a long-term basis for weeks to months in order to produce
anti-tumor effects [3]. This may be the reason that the
observed synergistic anti-tumor effect occurred after 10
days administration of the combination treatment.
In addition, apoptotic cells, expression of proteins related
to apoptosis (Bcl-2/Bax) and ultrastructural morphologi-
cal changes were also observed in the present study. Our
data showed that As-ODN-hTR and ATRA treatment
increased apoptotic cell death, and the most significant
increase in apoptosis was noted in the combination
treated group, as seen by TUNEL staining. Transmission
electron micrography revealed cells with morphologies
typical of apoptotic squamous carcinoma cells in all treat-
ment groups, whereas no ultrastructural changes were
observed in the control group. In the combination of As-
ODN-hTR and ATRA, treatment appears to effectively trig-
ger apoptosis in vivo. Therefore, the possible mechanism
underlying inhibition of tumor cell growth in our study
may occur via apoptosis.
Bcl-2 family proteins are key regulators of mitochondrial
integrity and comprise both pro- and anti-apoptotic pro-
teins [17]. Bcl-2 is considered to be an anti-apoptotic pro-
tein and protects cells against apoptosis [18]. Bax is a pro-
apoptotic inducer of Bcl-2 family proteins and forms het-
erodimers with a number of homologous anti-apoptotic
proteins (Bcl-2, Bcl-X, and Bad), which are then inacti-
vated to accelerate apoptosis [19]. Apoptosis is regulated
through the balance between pro- and anti-apoptotic pro-
teins. In the present study, expression of Bcl-2 and Bax was
detected. We observed that Bcl-2 expression was markedly
down-regulated in the As-ODN-hTR and ATRA treatment
groups, especially in the combination treated group, com-
pared with the control group. However, the expression of
Bax was similar in all groups. This result indicates that Bcl-
2 is involved in the apoptosis induced by As-ODN-hTR
and ATRA, whereas Bax is not a direct target of these treat-
ments. Recent studies have demonstrated that Bcl-2 is a
key regulator for both the retinoic acid-induced apoptotic
cell death and the telomerase activity. ATRA-induced cell
differentiation is proposed to affect Bcl-2 mRNA stability
indirectly by down-regulating the cellular levels of nucle-
olin, a potent Bcl-2 mRNA stabilization protein [20]. Also,
it is increasingly recognized that Bcl-2 gene is involved in
the regulation of telomerase activity induced by DNA-
damage-related signals [21,22]. Consistent with these
observations, close linkages between the administration
of ATRA and the expression of Bcl-2, the telomerase activ-
ity and the expression of Bcl-2 were observed in the
present study. Based on this observation, it was proposed
that Bcl-2 is an essential factor and plays an important
role in the apoptosis induced by ATRA and a decrease in
telomerase activity.
Telomerase activity of each group was detected by TRAP  assay, a PCR-based semiquantitative method Figure 3
Telomerase activity of each group was detected by 
TRAP assay, a PCR-based semiquantitative method. 
The average OD values of TRAP assay were shown as the 
mean ± SE (n = 10). Telomerase activity was significantly 
higher in S-ODN group and control group compared with 
other treatment groups. * P < 0.01, one-way ANOVA. A sig-
nificant interaction was observed between As-ODN-hTR and 
ATRA treatment. * * F = 4.507, P= 0.041, two-way ANOVA.BMC Cancer 2008, 8:159 http://www.biomedcentral.com/1471-2407/8/159
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Conclusion
Collectively, the results of the current in vivo study demon-
strate that in the combination of As-ODN-hTR and ATRA
results in a synergistic anti-tumor effect. This anti-tumor
effect may be mainly attributed to apoptosis induced by
decreased telomerase activity. Bcl-2 is involved in this
process, and appears to play an important role. Therefore,
these findings suggest that the combination of As-ODN-
hTR and ATRA may be a potential approach for the treat-
ment of human oral squamous cell carcinoma.
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Immunohistochemical staining for Bcl-2 (A-F) and Bax (G) expression in treatment groups and control group Figure 4
Immunohistochemical staining for Bcl-2 (A-F) and Bax (G) expression in treatment groups and control group. 
Sections showed strong Bcl-2 cytoplasmic staining of tumor cells in (A) control group and (B) S-ODN group, weak Bcl-2 cyto-
plasmic staining in (C) As group, (D) ATRA group and (E) S/ATRA group, extremely weak Bcl-2 staining in (F) As/ATRA 
treated group. (G) Similar moderate Bax cytoplasmic staining of tumor cells in all treatment groups. Representative section of 
As/ATRA group is shown. Scale bar = 50 μm. Computer-assisted quantitation of immunohistochemical staining was performed. 
(H) The average IODs of Bcl-2 and Bax were shown as the mean ± SE (n = 10). The average IODs in As-ODN and ATRA 
treated groups were significantly decreased as compared to S-ODN group and control group. * P < 0.01, one-way ANOVA. 
Significant interaction was observed between As-ODN-hTR and ATRA treatment. * * F = 35.836, P < 0.01, two-way ANOVA. 
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